A Study of CCX140-B in Subjects With FSGS

Phase 2 Completed 46 enrolled Amgen

RandomizedSequentialTriple-blindTreatment

Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia

Timeline

Start: 2018-05-17
Primary completion: 2020-02-19
Completion: 2020-02-19

Publications

Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CCX140-B	Small molecule	5 mg	Oral
Subject	CCX140-B	Small molecule	10 mg	Oral
Subject	CCX140-B	Small molecule	15 mg	Oral

A Study of CCX140-B in Subjects With FSGS

Summary

Timeline

Publications

Drugs

Indications